UiPath's ARR is set to hit $1.816B in FY26 (+9% YoY), driven by 98% gross and 110% net retention. Cloud ARR surged past $975M (+50% YoY) as enterprise adoption of AI-driven automation accelerates. Profitability improved with a 32% non-GAAP margin, $328M free cash flow, and $1.7B cash (zero debt).

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Monolithic Power Systems Inc. (NASDAQ:MPWR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/monolithic-lawsuit-submission-form?prid=137815&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of RLX Technology Inc. ("RLX Technology Inc.") (NYSE:RLX) concerning possible violations of federal securities laws. Citi downgraded RLX stock to Neutral from Buy on March 17, 2025, citing overseas headwinds from regulatory changes and an unfavorable product mix shift, and predicting that organic growth of RLX's overseas business will decelerate in 2025.

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Elastic N.V. (NYSE:ESTC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elastic-n-v-lawsuit-submission-form?prid=137818&wire=1 or contact Joseph E.

Host Hotels & Resorts is trading at a significant discount to its intrinsic value, offering a compelling investment opportunity despite its capital-intensive business model. The company has a solid balance sheet, investment-grade ratings, and a well-covered dividend yield of roughly 6%. Recession risks are mitigated by geographic diversification, a focus on affluent customers, and a share price that appears to be already partially discounting an economic downturn.

The accelerated pace of 5G deployment and demand for scalable infrastructure will likely help the Zacks Diversified Communication Services industry thrive despite geopolitical headwinds. DTEGY, TEF, and SHEN are well-positioned to capitalize on the infrastructure upgrade for seamless connectivity.

Stitch Fix (SFIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

LifeStance Health (LFST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

The mean of analysts' price targets for Adma Biologics (ADMA) points to a 39.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Frontier Group (ULCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Asana (ASAN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Energy Recovery (ERII). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 27.8% upside potential for ACM Research (ACMR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Quantum Computing Inc. remains a speculative bet with significant volatility. The market's hopes for QUBT's fast track to profitability seem to have taken a hit now. QUBT's Q4 2024 results showed a substantial net loss of $51.2 million, with increased OPEX and a 17% YoY revenue decline, despite a rise in gross profit margin. The company's future growth hinges on the operational launch of its Quantum Photonic Chip Foundry and securing preorders, but fierce competition limits its market share potential.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TransMedics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in TransMedics between February 23, 2023 and January 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , March 21, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against TransMedics Group, Inc. ("TransMedics" …

The gold market is a bit lower in the early hours of Friday, but we have also seen the market try to bounce a bit, showing that there are plenty of traders out there willing to start buying yet again.

CNBC's Frank Holland joins 'Squawk on the Street' to discuss why fifteen Wall Streets are trimming their price targets on FedEx.